Samuel (@meliyahhhh) header
Samuel (@meliyahhhh) profile picture

Investing full-time since 2012. Focused on uncovering overlooked growth stocks and getting positioned well before the crowd catches on.

California
Joined July 2012
Photo by Samuel (@meliyahhhh)Photo by Samuel (@meliyahhhh)Photo by Samuel (@meliyahhhh)Photo by Samuel (@meliyahhhh)Photo by Samuel (@meliyahhhh)Photo by Samuel (@meliyahhhh)Photo by Samuel (@meliyahhhh)Photo by Samuel (@meliyahhhh)Photo by Samuel (@meliyahhhh)Photo by Samuel (@meliyahhhh)
$ONDS Sentrycs, an anti-drone subsidiary of Ondas, has officially delivered its second mobile counter-unmanned aircraft system (C-UAS) platform to the New York Police Department (NYPD) Counter-Terrorism Team this week, facilitated by its partner, Accelerated Tactical. This repeat order serves as a powerful catalyst for the commercial expansion of Ondas’s solutions within the public safety and homeland security sectors. Unlike traditional RF jammers that disrupt civilian communications, Sentrycs' Cyber-over-RF (CoRF) protocol-manipulation tech safely detects, tracks, and takes control of rogue drones with zero collateral interference—making it ideal for Tier-1 urban environments like NYC. Following recent wins with European law enforcement and defense integrations (including Lockheed Martin's Sanctum™), landing the NYPD cements ONDS as a go-to counter-UAS standard for major U.S. metro police and homeland security agencies.
1
1
16
1,119
$CBRS Financial reports indicate that the company’s remaining performance obligations (backlog) have reached $26.1 billion. A significant portion of this stems from agreements signed with OpenAI, providing a robust pipeline for long-term computing capacity delivery. Approximately 33% of this backlog—roughly $8.6 billion—is expected to be recognized as revenue over the next 24 months, leading up to September 2028, offering exceptional visibility into the company’s short- to medium-term performance. The company has provided a core revenue guidance of $940 million to $960 million for 2026. Furthermore, management anticipates that revenue will triple by 2027—reaching the neighborhood of $3 billion—signaling an exponential surge in performance as contracted demand is fulfilled and converted into recognized revenue.
5
43
3,075
$CAPR Short are digging deep but we're still holding. Expect some gut wrenching swings between today and Friday.
2
1
5
637
$RDW Redwire Wins Fourth Contract This Month — RDW Signs New $15M Satellite Panel Order,Redwire will supply its ELSA wings to power AscendArc’s geosynchronous communications satellite. The company said it had more than 65 solar array wings delivered or under development as of November 2026. Earlier this month, Redwire reported that its backlog had surged 51% from December 2025 to a record $619.7 million at the end of Q3. The company expects full-year 2026 revenue of $450 million to $500 million.
3
1
12
1,459
$HUMA Humacyte has submitted a supplemental Biologics License Application to the FDA—supported by three Phase 3 studies showing women gained usable dialysis access over three months sooner and spent more time catheter-free—to add hemodialysis access as a second approved indication for its bioengineered blood vessel (Symvess), with a Priority Review request and a 60-day FDA filing assessment ahead.
5
1
30
1,119
$CLOV With 2027 revenue projections reaching up to $4.4B on the back of strong Medicare Advantage membership growth, Clover Health is trading at roughly 0.57x forward sales—an attractive valuation for a profitable insurer boasting a 5-star PPO rating, top-ranked HEDIS clinical outcomes, and one of the best medical cost ratios (MCR) in the sector powered by Clover Assistant.
5
23
1,045
$FRMI from a Reddit user.
1
1
12
1,655
$CIFR Gap on Daily. Let's fill it! Sooooooo oversold.
1
1
18
1,033
$LPTH LPTH customer Elbit Systems reported a very strong quarter yesterday announcing a record backlog of $33 billion. LPTH is supplying Elbit’s U.S. subsidiary Twenty Six Defense with G5 cameras for the Customs and Border Patrol program.
4
402
$PLUG THE DIFFERENCE Plug has an electrolyzer contract for Orica's Harbor Valley Hub. Plug will either deliver Ten "GenEco" 10 MW electrolyzers or 2 "GenEco Scale" 20 MW systems and 1" GenEco" electrolyzer for the project. There is a difference between "GenEco Scale" and "GenEco. "GenEco Scale" is a complete 20 MW system and "GenEco" is a customized unit. 50 MWs is 50 MWs and since "GenEco Scale" saves 30 - 40% on capital layout it could be a perfect fit for Orica 50 MW facility. It could be the 4-month delay for any progress announcement is because Kent modified the FEED parameters to accommodate Plug's 20 MW “GenEco Scale System”. We will know soon enough what Orica wants delivered.
3
7
558
$ENVX On November 18, 2026, Enovix Corporation announced a positive market catalyst by distributing a free warrant dividend (one ENVXW warrant exercisable at $3.00 for every four common shares held) to shareholders of record as of November 13, aimed at boosting liquidity and funding battery production expansion.
1
1
3
809
$OSCR Oscar Health is expanding its partnership with Midwest grocery giant Hy-Vee statewide across Iowa and launching in Kansas City and Omaha for 2027 open enrollment, unlocking a big new wave of member and premium growth. By combining access to top regional hospital networks, its Oswell AI health assistant, and everyday Hy-Vee grocery and clinic perks across both individual and employer channels, OSCR is building a sticky, high-converting edge that sets up strong revenue momentum heading into 2027.
1
6
320
$NFLX Netflix is flashing clear signs of institutional accumulation around the $59.50–$60.00 support zone after its 5-day pullback. Looking at the chart from November 12 to November 18, four consecutive days of heavy volume spikes at the open and close (highlighted by the yellow circles) show big buyers stepping in to absorb selling pressure right near the $59.41 multi-year low. While price is still working back toward its VWAP and 200-period moving average, RSI (14) has steadily climbed out of oversold territory back into the 45–50 range—building a textbook base for a relief bounce as NFLX trades at a steep valuation discount near 17x earnings alongside its massive $4.8 billion quarterly buyback program.
1
1
5
612
$JMIA Since 2018, Jumia has gone through this same cycle multiple times; the current situation appears to present an excellent opportunity. Bolstered by several positive catalysts—including recent insider buying, a newly announced share repurchase program, and market rumors of a potential acquisition by Amazon at $7.00 per share—the stock is well-positioned to gain strong momentum and break through the $6.00 mark before the end of the year.
1
3
754
$CRWD is catching major bullish momentum across both Wall Street and technicals! Nvidia’s Q3 revenue & EPS beat lifted the broader tech sector, helping push CrowdStrike higher. 31 of 40 analysts rate CRWD a "Buy" with an average PT of $258.41—led by TD Cowen ($280 PT) and Cantor Fitzgerald raising its target to $275. Trading ~34% above its 200-day moving average ($174.81) with May’s bullish "golden cross" keeping the long-term uptrend intact
1
4
378
$SPMC Sound Point Meridian Capital is offering a rare combination of massive monthly income and deep asset-value upside: • 25%+ Annualized Monthly Yield: Declared $0.13/share monthly dividends locked in through Q1 2027 (Jan, Feb, Mar)—translating to a ~25.4%–26.7% forward yield near $6.00. • ~30% Discount to NAV: Trading around $6.00 against an estimated NAV of $8.41–$8.51/share (as of Oct 31), giving investors a massive ~28%–30% margin of safety. • Rising NII & Fee Waivers: Monthly Net Investment Income (NII) climbed from ~$0.08/sh in Q1 to ~$0.11/sh in October, steadily closing in on full dividend coverage—boosted by voluntary management & incentive fee waivers through year-end. Upgraded to Zacks Rank #1 (Strong Buy) on Nov 13 with a $9.33 consensus price target (+50% upside). Nearly 59% institutionally owned (including Bank of America, Goldman Sachs, and Virtus Private Credit ETF) alongside recent net insider buying. 2027 Catalysts: With CLO issuance surging (+37% QoQ) and loan spreads bottoming out, improving equity arbitrage sets the stage for full dividend coverage and potential distribution hikes in 2027.
1
143
$SOXL just got back in and holding till 60 by friday. Anthropic’s blockbuster IPO serves as a powerful catalyst for SOXL by reigniting risk appetite across the entire AI infrastructure ecosystem and validating massive long-term semiconductor demand. Backed by roughly $895 billion in multi-year computing and infrastructure commitments—including a landmark chip and networking financing deal with Broadcom (a core SOXL constituent)—Anthropic’s strong market debut reinforces institutional conviction in sustained AI hardware spending. Because SOXL delivers 3x daily leverage on top semiconductor leaders like NVIDIA, AMD, and Broadcom, even a modest 2% to 3% IPO-driven rally across chip stocks translates into an explosive 6% to 9% surge in SOXL.
2
4
497
$SRXH LFG <- Almost time! 20m buy back ACTIVE No debt 60M+ assets cash. Min NAV $3.35 Gap fill $6 +
1
2
5
456
$QBTS Trading near its 52-week low, D-Wave Quantum continues to expand its commercial footprint through federal funding and major enterprise contracts. • $100M U.S. CHIPS Act Support: Secured up to $100M in federal funding to advance quantum computing development. • Surging Bookings & Backlog: Q3 2026 data reflects triple-digit year-over-year growth in bookings and backlog, bolstered by large-scale system sales to academic and Fortune 100 partners. • Global & Defense Deployments: Expanded international installations, optimization projects with major telecom providers, and defense-related industry partnerships. • Financial Strength & Recognition: Maintained a strong cash and investment position with minimal debt, alongside industry recognition in major market reports
2
3
387
$MSOS Policy Tailwinds Update 📈 The White House has reaffirmed President Trump’s steadfast support for cannabis reform, sustaining policy momentum at the federal level for U.S. Multi-State Operators (MSOS): Clear Stance from the White House: Spokesperson Allison Schuster reiterated President Trump’s commitment to accelerating the rescheduling of cannabis and establishing a science-based regulatory framework. Prohibitions related to hemp are expected to see another extension within the omnibus spending bill—a direct positive for compliant, licensed MSOS. Progress on "Schedule III" Status: Earlier this year, medical cannabis—already legalized at the state level—was proposed for reclassification to "Schedule III" (a move that would provide significant relief from the 280E tax provision). Furthermore, hearings regarding the comprehensive rescheduling of cannabis concluded in July, with the process now awaiting final approval from the Drug Enforcement Administration (DEA). With the realization of 280E tax relief and the anticipated final action from the DEA, MSOS is poised for a valuation re-rating driven by major policy tailwinds.
1
2
7
719